Archived explainer. For the current picture see today's BHVN page.
BIOHAVEN LTD (BHVN) is down -2.72% in the latest session. Our newswire has captured 1 story on BHVN across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
BHVN stock fell 2.72 percent to $15.02 on Monday. The decline followed a -2.8 percent opening gap from the prior close of $15.44. The stock has traded in a narrow range during the session with a high of $15.79 and a low of $15.00. The move comes amid mixed news on the company’s clinical pipeline and recent analyst activity.
Biohaven announced it will present new clinical data on BHV-1530 at the ESMO Congress, a novel FGFR3-directed ADC with a proprietary Topoisomerase I payload. The company also announced a new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®). Early clinical activity from the Phase 1 dose-escalation data showed signs of tumor reduction. Meanwhile, a recent report warned that Biohaven’s lead drug may struggle to stand out in its competitive space. B of A Securities downgraded Biohaven to Underperform and lowered its price target to $11. These developments contributed to investor caution.
BHVN has a market cap of $2.3 billion and is unprofitable with an EPS TTM of -5.44. The stock has a high beta of 3.14 and has traded between $7.48 and $18.57 over the past 52 weeks. The current session has seen 0.2 million shares traded, which is 0.1 times the 3-month daily average. The stock opened at $15.00 and has traded in a tight range since. The 30-day average sentiment score is 55 out of 100, while the 7-day score improved to 63.
Investors should monitor the company’s upcoming earnings and any further developments in its clinical trials. Coverage breadth is currently limited to one story in the last 36 hours.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®) Early clinical activity observed: Phase 1 dose-escalation data show early tumor reductions in patients with Fibroblast Growth Factor Receptor (FGFR)3-altered...
More on BHVN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BHVN move explainers: 2026-07-20 · 2026-07-13 · 2026-07-11